304 related articles for article (PubMed ID: 32240714)
1. Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications.
Carrillo-Reixach J; Torrens L; Simon-Coma M; Royo L; Domingo-Sàbat M; Abril-Fornaguera J; Akers N; Sala M; Ragull S; Arnal M; Villalmanzo N; Cairo S; Villanueva A; Kappler R; Garrido M; Guerra L; Sábado C; Guillén G; Mallo M; Piñeyro D; Vázquez-Vitali M; Kuchuk O; Mateos ME; Ramírez G; Santamaría ML; Mozo Y; Soriano A; Grotzer M; Branchereau S; de Andoin NG; López-Ibor B; López-Almaraz R; Salinas JA; Torres B; Hernández F; Uriz JJ; Fabre M; Blanco J; Paris C; Bajčiová V; Laureys G; Masnou H; Clos A; Belendez C; Guettier C; Sumoy L; Planas R; Jordà M; Nonell L; Czauderna P; Morland B; Sia D; Losic B; Buendia MA; Sarrias MR; Llovet JM; Armengol C
J Hepatol; 2020 Aug; 73(2):328-341. PubMed ID: 32240714
[TBL] [Abstract][Full Text] [Related]
2. Identification and experimental validation of druggable epigenetic targets in hepatoblastoma.
Clavería-Cabello A; Herranz JM; Latasa MU; Arechederra M; Uriarte I; Pineda-Lucena A; Prosper F; Berraondo P; Alonso C; Sangro B; García Marin JJ; Martinez-Chantar ML; Ciordia S; Corrales FJ; Francalanci P; Alaggio R; Zucman-Rossi J; Indersie E; Cairo S; Domingo-Sàbat M; Zanatto L; Sancho-Bru P; Armengol C; Berasain C; Fernandez-Barrena MG; Avila MA
J Hepatol; 2023 Oct; 79(4):989-1005. PubMed ID: 37302584
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of SFRP1 is a protumorigenic event in hepatoblastoma and correlates with beta-catenin mutations.
Regel I; Eichenmüller M; Mahajan UM; Hagl B; Benitz S; Häberle B; Vokuhl C; von Schweinitz D; Kappler R
J Cancer Res Clin Oncol; 2020 May; 146(5):1153-1167. PubMed ID: 32189106
[TBL] [Abstract][Full Text] [Related]
4. The genomic landscape of hepatoblastoma and their progenies with HCC-like features.
Eichenmüller M; Trippel F; Kreuder M; Beck A; Schwarzmayr T; Häberle B; Cairo S; Leuschner I; von Schweinitz D; Strom TM; Kappler R
J Hepatol; 2014 Dec; 61(6):1312-20. PubMed ID: 25135868
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of
Beck A; Trippel F; Wagner A; Joppien S; Felle M; Vokuhl C; Schwarzmayr T; Strom TM; von Schweinitz D; Längst G; Kappler R
Clin Epigenetics; 2018; 10():27. PubMed ID: 29507645
[TBL] [Abstract][Full Text] [Related]
6. DLK1/DIO3 locus upregulation by a β-catenin-dependent enhancer drives cell proliferation and liver tumorigenesis.
Sanceau J; Poupel L; Joubel C; Lagoutte I; Caruso S; Pinto S; Desbois-Mouthon C; Godard C; Hamimi A; Montmory E; Dulary C; Chantalat S; Roehrig A; Muret K; Saint-Pierre B; Deleuze JF; Mouillet-Richard S; Forné T; Grosset CF; Zucman-Rossi J; Colnot S; Gougelet A
Mol Ther; 2024 Apr; 32(4):1125-1143. PubMed ID: 38311851
[TBL] [Abstract][Full Text] [Related]
7. Cross talk between RNA N6-methyladenosine methyltransferase-like 3 and miR-186 regulates hepatoblastoma progression through Wnt/β-catenin signalling pathway.
Cui X; Wang Z; Li J; Zhu J; Ren Z; Zhang D; Zhao W; Fan Y; Zhang D; Sun R
Cell Prolif; 2020 Mar; 53(3):e12768. PubMed ID: 31967701
[TBL] [Abstract][Full Text] [Related]
8. A novel risk stratification model based on the Children's Hepatic Tumours International Collaboration-Hepatoblastoma Stratification and deoxyribonucleic acid methylation analysis for hepatoblastoma.
Kondo T; Honda S; Suzuki H; Ito YM; Kawakita I; Okumura K; Ara M; Minato M; Kitagawa N; Tanaka Y; Tanaka M; Shinkai M; Hishiki T; Watanabe K; Ida K; Takatori A; Hiyama E; Taketomi A
Eur J Cancer; 2022 Sep; 172():311-322. PubMed ID: 35816972
[TBL] [Abstract][Full Text] [Related]
9. A combined clinical and biological risk classification improves prediction of outcome in hepatoblastoma patients.
Cairo S; Armengol C; Maibach R; Häberle B; Becker K; Carrillo-Reixach J; Guettier C; Vokuhl C; Schmid I; Buendia MA; Branchereau S; von Schweinitz D; Kappler R
Eur J Cancer; 2020 Dec; 141():30-39. PubMed ID: 33125945
[TBL] [Abstract][Full Text] [Related]
10. High expression of IGF2-derived intronic miR-483 predicts outcome in hepatoblastoma.
Weiss JBW; Wagner AE; Eberherr C; Häberle B; Vokuhl C; von Schweinitz D; Kappler R
Cancer Biomark; 2020; 28(3):321-328. PubMed ID: 32390604
[TBL] [Abstract][Full Text] [Related]
11. β-Catenin mutations as determinants of hepatoblastoma phenotypes in mice.
Zhang W; Meyfeldt J; Wang H; Kulkarni S; Lu J; Mandel JA; Marburger B; Liu Y; Gorka JE; Ranganathan S; Prochownik EV
J Biol Chem; 2019 Nov; 294(46):17524-17542. PubMed ID: 31597698
[TBL] [Abstract][Full Text] [Related]
12. Targeting excessive MYCN expression using MLN8237 and JQ1 impairs the growth of hepatoblastoma cells.
Eberherr C; Beck A; Vokuhl C; Becker K; Häberle B; Von Schweinitz D; Kappler R
Int J Oncol; 2019 May; 54(5):1853-1863. PubMed ID: 30864675
[TBL] [Abstract][Full Text] [Related]
13. Genetic and epigenetic basis of hepatoblastoma diversity.
Nagae G; Yamamoto S; Fujita M; Fujita T; Nonaka A; Umeda T; Fukuda S; Tatsuno K; Maejima K; Hayashi A; Kurihara S; Kojima M; Hishiki T; Watanabe K; Ida K; Yano M; Hiyama Y; Tanaka Y; Inoue T; Ueda H; Nakagawa H; Aburatani H; Hiyama E
Nat Commun; 2021 Sep; 12(1):5423. PubMed ID: 34538872
[TBL] [Abstract][Full Text] [Related]
14. Hepatoblastomas with carcinoma features represent a biological spectrum of aggressive neoplasms in children and young adults.
Sumazin P; Peters TL; Sarabia SF; Kim HR; Urbicain M; Hollingsworth EF; Alvarez KR; Perez CR; Pozza A; Najaf Panah MJ; Epps JL; Scorsone K; Zorman B; Katzenstein H; O'Neill AF; Meyers R; Tiao G; Geller J; Ranganathan S; Rangaswami AA; Woodfield SE; Goss JA; Vasudevan SA; Heczey A; Roy A; Fisher KE; Alaggio R; Patel KR; Finegold MJ; López-Terrada DH
J Hepatol; 2022 Oct; 77(4):1026-1037. PubMed ID: 35577029
[TBL] [Abstract][Full Text] [Related]
15. Blocking the hedgehog pathway inhibits hepatoblastoma growth.
Eichenmüller M; Gruner I; Hagl B; Häberle B; Müller-Höcker J; von Schweinitz D; Kappler R
Hepatology; 2009 Feb; 49(2):482-90. PubMed ID: 19177589
[TBL] [Abstract][Full Text] [Related]
16. HGF/c-Met related activation of β-catenin in hepatoblastoma.
Purcell R; Childs M; Maibach R; Miles C; Turner C; Zimmermann A; Sullivan M
J Exp Clin Cancer Res; 2011 Oct; 30(1):96. PubMed ID: 21992464
[TBL] [Abstract][Full Text] [Related]
17. Genomic analysis of hepatoblastoma identifies distinct molecular and prognostic subgroups.
Sumazin P; Chen Y; Treviño LR; Sarabia SF; Hampton OA; Patel K; Mistretta TA; Zorman B; Thompson P; Heczey A; Comerford S; Wheeler DA; Chintagumpala M; Meyers R; Rakheja D; Finegold MJ; Tomlinson G; Parsons DW; López-Terrada D
Hepatology; 2017 Jan; 65(1):104-121. PubMed ID: 27775819
[TBL] [Abstract][Full Text] [Related]
18. Hepatoblastomas exhibit marked
Rivas MP; Aguiar TFM; Maschietto M; Lemes RB; Caires-Júnior LC; Goulart E; Telles-Silva KA; Novak E; Cristofani LM; Odone V; Cypriano M; de Toledo SRC; Carraro DM; Escobar MQ; Lee H; Johnston M; da Costa CML; da Cunha IW; Tasic L; Pearson PL; Rosenberg C; Timchenko N; Krepischi ACV
Tumour Biol; 2020 Dec; 42(12):1010428320977124. PubMed ID: 33256542
[TBL] [Abstract][Full Text] [Related]
19. New insights into diagnosis and therapeutic options for proliferative hepatoblastoma.
Hooks KB; Audoux J; Fazli H; Lesjean S; Ernault T; Dugot-Senant N; Leste-Lasserre T; Hagedorn M; Rousseau B; Danet C; Branchereau S; Brugières L; Taque S; Guettier C; Fabre M; Rullier A; Buendia MA; Commes T; Grosset CF; Raymond AA
Hepatology; 2018 Jul; 68(1):89-102. PubMed ID: 29152775
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA expression might predict prognosis of epithelial hepatoblastoma.
Gyugos M; Lendvai G; Kenessey I; Schlachter K; Halász J; Nagy P; Garami M; Jakab Z; Schaff Z; Kiss A
Virchows Arch; 2014 Apr; 464(4):419-27. PubMed ID: 24570391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
